SEC Company Response from Akari Therapeutics Plc (AKTX) (CIK 0001541157) (AKTX) — Apr 15, 2020
Akari Therapeutics Plc (AKTX) (CIK 0001541157)
Date: April 15, 2020 · CIK: 0001541157 · Accession: 0001104659-20-046531
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-237389
Letter
Akari Therapeutics, PLC
75/76 Wimpole Street
London W1G 9RT
United Kingdom
April 14, 2020
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Akari Therapeutics, PLC
Registration Statement on Form F-3
File No. 333-237389
VIA EDGAR
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Akari Therapeutics, PLC (the “Registrant”) hereby respectfully requests that the effectiveness of the Registration Statement on Form F-3 (File No. 333-237389) of the Registrant (the “Registration Statement”) be accelerated so that it will be declared effective at 4:30 p.m., Eastern Time, on April 16, 2020 or as soon thereafter as may be practicable.
The undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel, McDermott Will & Emery LLP, by calling Gary Emmanuel at (212) 547-5541. The Company hereby authorizes Mr. Emmanuel to orally modify or withdraw this request for acceleration.
Very truly yours,
AKARI THERAPEUTICS, PLC
Show Raw Text
CORRESP
1
filename1.htm
Akari Therapeutics, PLC
75/76 Wimpole Street
London W1G 9RT
United Kingdom
April 14, 2020
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
Akari Therapeutics, PLC
Registration Statement on Form F-3
File No. 333-237389
VIA EDGAR
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities
Act of 1933, as amended, Akari Therapeutics, PLC (the “Registrant”) hereby respectfully requests that the effectiveness
of the Registration Statement on Form F-3 (File No. 333-237389) of the Registrant (the “Registration Statement”)
be accelerated so that it will be declared effective at 4:30 p.m., Eastern Time, on April 16, 2020 or as soon thereafter as may
be practicable.
The undersigned respectfully requests that
it be notified of the effectiveness of the Registration Statement by telephone call to our counsel, McDermott Will & Emery
LLP, by calling Gary Emmanuel at (212) 547-5541. The Company hereby authorizes Mr. Emmanuel to orally modify or withdraw this request
for acceleration.
Very truly yours,
AKARI THERAPEUTICS, PLC
By:
/s/ Clive Richardson
Name:
Clive Richardson
Title:
Chief Executive Officer and Chief Operating Officer